Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

NCT06749054 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Oral Lenacapavir
DRUG: Subcutaneous Lenacapavir
DRUG: Optimized Background Regimen (OBR)

Sponsor

Gilead Sciences